Credit: Source: Tesaro.
Source: Tesaro.
Because Moulder has had significant success with cancer drugs in the past, and he's shown a willingness to sell to suitors, Tesaro may be worth keeping a close eye on, too.
Following footsteps
Owning biotech companies backed by proven leaders can be a recipe for success, but there's no guarantee that Frost's, Moulder's, and Soon-Shiong's past successes will translate into profit for investors in Opko Health, Tesaro, or Sorrento Therapeutics. For that reason, investors should approach these companies cautiously. However, for risk-tolerant investors, it may be worth considering each of these three companies.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article Biotech Billionaires: Can They Do It Again? originally appeared on Fool.com.
Todd Campbell has no position in any stocks mentioned. Todd owns the equity research firm E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
